287 related articles for article (PubMed ID: 28341735)
1. Venous thromboembolism is associated with graft-
Kekre N; Kim HT; Ho VT; Cutler C; Armand P; Nikiforow S; Alyea EP; Soiffer RJ; Antin JH; Connors JM; Koreth J
Haematologica; 2017 Jul; 102(7):1185-1191. PubMed ID: 28341735
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.
Hueso T; Gauthier J; Joncquel Chevalier-Curt M; Magro L; Coiteux V; Dulery R; Carpentier B; Labreuche J; Damaj G; Yakoub-Agha I; Seguy D
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):908-917.e2. PubMed ID: 29258901
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.
Zahid MF; Murad MH; Litzow MR; Hogan WJ; Patnaik MS; Khorana A; Spyropoulos AC; Hashmi SK
Ann Hematol; 2016 Sep; 95(9):1457-64. PubMed ID: 27103008
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism incidence in hematologic malignancies.
Kekre N; Connors JM
Blood Rev; 2019 Jan; 33():24-32. PubMed ID: 30262170
[TBL] [Abstract][Full Text] [Related]
6. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
7. Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.
Rabian F; Porcher R; Sicre de Fontbrune F; Lioure B; Laplace A; Nguyen S; Tabrizi R; Vigouroux S; Tomowiak C; Maillard N; Suarez F; Delage J; Peffault de Latour R; Socié G;
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1721-1724. PubMed ID: 27246370
[TBL] [Abstract][Full Text] [Related]
8. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
Dunbar EM; Buzzeo MP; Levine JB; Schold JD; Meier-Kriesche HU; Reddy V
Haematologica; 2008 Dec; 93(12):1852-8. PubMed ID: 18945751
[TBL] [Abstract][Full Text] [Related]
9. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.
Labrador J; Lopez-Anglada L; Perez-Lopez E; Lozano FS; Lopez-Corral L; Sanchez-Guijo FM; Vazquez L; Perez Rivera JA; Martin-Herrero F; Sanchez-Barba M; Guerrero C; del Cañizo MC; Caballero MD; San Miguel JF; Alberca I; Gonzalez-Porras JR
Haematologica; 2013 Mar; 98(3):437-43. PubMed ID: 22899581
[TBL] [Abstract][Full Text] [Related]
10. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
13. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
14. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
[TBL] [Abstract][Full Text] [Related]
16. Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation.
Avery J; Guffey D; Ma S; Basom R; Lee SJ; Garcia D; Rojas Hernandez CM; Li A; Martens KL
Thromb Res; 2023 Sep; 229():1-6. PubMed ID: 37356171
[TBL] [Abstract][Full Text] [Related]
17. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.
Holmqvist AS; Chen Y; Wu J; Battles K; Bhatia R; Francisco L; Hageman L; Kung M; Ness E; Parman M; Salzman D; Wadhwa A; Winther JF; Rosenthal J; Forman SJ; Weisdorf DJ; Armenian SH; Arora M; Bhatia S
JAMA Oncol; 2018 Dec; 4(12):e182453. PubMed ID: 30054602
[TBL] [Abstract][Full Text] [Related]
19. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Lam W; Storek J; Li H; Geddes M; Daly A
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28199755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
